Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes-Reference-Cited by-同舟云学术

Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes

Published:2019-03-22 Issue:9 Volume:120 Page:913-921
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bonnefoi Hervé, ,MacGrogan Gaetan,Poncet Coralie,Iggo Richard,Pommeret Fanny,Grellety Thomas,Larsimont Denis,Bécette Véronique,Kerdraon Olivier,Bibeau Frédéric,Ghnassia Jean-Pierre,Picquenot Jean-Michel,Thomas Jeremy,Tille Jean-Christophe,Slaets Leen,Bodmer Alexandre,Bergh Jonas,Cameron David

Funder

European Organisation for Research and Treatment of Cancer

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0420-y.pdf

Reference26 articles.

1. Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., Fumoleau, P. & Larsimont, D. et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24, 4660–4671 (2005).

2. DM, DoaneA. S., Lal, Donaton, P., Zhang, M., Hudis, L., Gerald, C. & An, W. L. Estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25, 1–15 (2006).

3. Guedj, M., Marisa, L., de Reynies, A., Orsetti, B., Schiappa, R. & Bibeau, F. et al. A refined molecular taxonomy of breast cancer. Oncogene 31, 1196–1206 (2012).